Lord, Abbett & Co
BBIO icon

Lord, Abbett & Co’s BridgeBio Pharma BBIO Stock Holding History

Lord, Abbett & Co’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$37.2M Sell
499,659
-523,682
-51% -$36.7M 0.11% 217
2026
Q1 		$76M Buy
1,023,341
+241,996
+31% +$17.5M 0.25% 111
2025
Q4 		$59.8M Sell
781,345
-95,536
-11% -$6.27M 0.18% 142
2025
Q3 		$45.5M Sell
876,881
-526,860
-38% -$25.7M 0.14% 180
2025
Q2 		$60.6M Buy
1,403,741
+545,819
+64% +$19.9M 0.2% 131
2025
Q1 		$29.7M Buy
+857,922
New +$28.9M 0.11% 226
2024
Q2 		– Sell
-2,804,394
Closed -$86.7M – 523
2024
Q1 		$86.7M Sell
2,804,394
-293,688
-9% -$9.99M 0.28% 109
2023
Q4 		$125M Buy
3,098,082
+2,303,681
+290% +$69.2M 0.44% 66
2023
Q3 		$20.9M Buy
+794,401
New +$22.5M 0.08% 318
2021
Q4 		– Sell
-796,668
Closed -$37.3M – 606
2021
Q3 		$37.3M Sell
796,668
-25,350
-3% -$1.36M 0.09% 325
2021
Q2 		$50.1M Sell
822,018
-408,867
-33% -$23.3M 0.12% 258
2021
Q1 		$75.8M Buy
1,230,885
+156,919
+15% +$10.3M 0.19% 168
2020
Q4 		$76.4M Buy
1,073,966
+459,242
+75% +$22.2M 0.2% 158
2020
Q3 		$23.1M Sell
614,724
-316,009
-34% -$9.94M 0.07% 353
2020
Q2 		$30.4M Sell
930,733
-58,534
-6% -$1.78M 0.11% 296
2020
Q1 		$28.7M Buy
989,267
+30,083
+3% +$933K 0.13% 253
2019
Q4 		$33.6M Buy
959,184
+158,380
+20% +$4.39M 0.11% 286
2019
Q3 		$17.2M Buy
800,804
+307,462
+62% +$8.51M 0.06% 432
2019
Q2 		$13.3M Buy
+493,342
New +$13.4M 0.04% 500

Other funds holding BBIO

JT
Jupiter Topco New York $245B AUM
KKRC
Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
ACM
Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return

Lord, Abbett & Co's BBIO Position: Q2 2026 in Review

Lord, Abbett & Co reduced its BridgeBio Pharma (BBIO) stake by 51% in Q2 2026, selling an estimated $36.7M and leaving 499,659 shares worth $37.2M. The position accounts for 0.11% of the portfolio, ranked #217.

Lord, Abbett & Co first reported a position in BBIO in Q2 2019 and has held it in 19 quarters since. The position peaked at $125M in Q4 2023. 474 funds tracked by Wall St. Rank hold BBIO as of Q2 2026.

  • Lord, Abbett & Co held 499,659 shares of BridgeBio Pharma worth $37.2M as of Q2 2026.
  • Lord, Abbett & Co sold 523,682 BridgeBio Pharma shares in Q2 2026, an estimated $36.7M.
  • BridgeBio Pharma made up 0.11% of Lord, Abbett & Co's portfolio in Q2 2026, its #217 holding.
  • Lord, Abbett & Co first reported a position in BridgeBio Pharma in Q2 2019 and has held it in 19 quarters since.
  • Lord, Abbett & Co's BridgeBio Pharma position peaked at $125M in Q4 2023.
  • 474 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2026.

Based on Lord, Abbett & Co's 13F filing for Q2 2026, filed 14 Aug 2026.